Boron neutron capture therapy for malignant melanoma： first clinical case report in China

作     者：Zhong Yong Zewen Song Yongmao Zhou Tong Liu Zizhu Zhang Yanzhong Zhao Yang Chen Congjun Jin Xiang Chen Jianyun Lu Rui Han Pengzhou Li Xulong Sun Guohui Wang Guangqing Shi Shaihong Zhu 

作者机构：Department of Nuclear Medicine the Third Xiangya Hospital of Central South University Changsha 410013 China Department of Oncology the Third Xiangya Hospital of Central South University Changsha 410013 China China Zhongyuan Engineering Corporation Beijing 100191 China Department of Nuclear Medicine China Nuclear Industry Beijing 401 Hospital Beijing 102413 China Medical Experimental Center the Third Xiangya Hospital of Central South University Changsha 410013 China Department of Dermatology Xiangya Hospital of Central South University Changsha 410008 China Department of Dermatology the Third Xiangya Hospital of Central South University Changsha 410013 China Department of Anesthesiology the Third Xiangya Hospital of Central South University Changsha 410013 China Department of General Surgery the Third Xiangya Hospital of Central South University Changsha 410013 China 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2016年第28卷第6期

页      面：634-640页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Science&Technology Pillar Program during the 12th Five-Year Plan Period(No.2013BAI01B08) the Major Program of the National Natural Science Foundation of China(No.51290295) 

主　　题：In-hospital neutron irradiator boron neutron capture therapy malignant melanoma 

摘      要：A phase Ⅰ/Ⅱ clinical trial for treating malignant melanoma by boron neutron capture therapy（BNCT） was designed to evaluate whether the world＇s first in-hospital neutron irradiator（IHNI） was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography（PET/CT） scan, pathological analysis and gross examination, the patient showed a complete response to BNCT,indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals.